Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call TranscriptSeeking Alpha • 07/30/25
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/30/25
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 EarningsInvestors Business Daily • 07/30/25
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 07/29/25
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive QuartersThe Motley Fool • 07/18/25
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?Zacks Investment Research • 07/11/25
Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead24/7 Wall Street • 07/01/25
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025GlobeNewsWire • 06/25/25
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?The Motley Fool • 06/25/25
Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic MigraineGlobeNewsWire • 06/23/25
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer TherapyZacks Investment Research • 06/17/25
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-OncologyPRNewsWire • 06/16/25
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight QuartersThe Motley Fool • 06/16/25
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/10/25
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff ThreatsZacks Investment Research • 06/09/25
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference TranscriptSeeking Alpha • 06/05/25
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early SettlementGlobeNewsWire • 06/03/25
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025GlobeNewsWire • 05/31/25
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to DateGlobeNewsWire • 05/31/25
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy DayGlobeNewsWire • 05/29/25